Full Press Release Details
InMed Pharmaceuticals to Participate in Cowen's
November 23, 2021 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a leader in the
development, manufacturing and commercialization of rare cannabinoids, today announced that InMed's management team is scheduled
to participate in Cowen's 4th Annual Cannabis Conference to be held virtually on November 29 - December 1, 2021.
Cowen's 4th Annual Cannabis Conference
Date: November 29 - December 1, 2021
Management will be available for virtual one-on-one meetings with institutional
and corporate clients of the firm. To request 1-on-1 meetings with the Company, please contact your Cowen institutional representative
or visit the conference website at https://www.cowen.com/conferences-and-events/4th-annual-cannabis-conference/
Cowen's 4th Annual Cannabis Conference is a three-day conference comprising
of topical panel discussions with C-Suite presenters, hosted by Cowen Research and Washington Research Group analysts, and virtual
one-on-one meetings.
InMed Pharmaceuticals is a global leader in the development, manufacturing and commercialization of rare cannabinoids. Together with
its subsidiary, BayMedica, the Company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets,
including pharmaceutical and health and wellness. InMed is a clinical-stage company developing a pipeline of rare cannabinoid therapeutics
and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more
information, visit www.inmedpharma.com.
Senior Director, Investor Relations
Joe Green/Laine Yonker
T: +1.646.653.7030/+1.646.653.7035
Cautionary Note Regarding Forward-Looking Information:
This news release contains "forward-looking
information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning
of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to
a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.
Forward-looking information in this news release includes statements about: participating in Cowen's 4th Annual Cannabis Conference;
delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs; and developing a pipeline
of cannabinoid-based pharmaceutical drug candidates. All forward-looking information herein is qualified in its entirety by this cautionary
statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result
of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except